Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-928 vs Docetaxel in Advanced NSCLC
NCT07217301Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Nov 2025
- Primary completion
- Nov 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of IBI363 in non-small cell lung cancer (NSCLC), sponsored by Takeda. Started Nov 2025; status: recruiting.
02
Drugs
IBI363
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07217301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217301.